Takuya Iwaki

发表

Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer

H. Kume, T. Ushiku, Y. Fujii, 2022, Scientific Reports.

Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients

H. Kume, S. Taguchi, Motofumi Suzuki, 2023, Scientific Reports.

PSA doubling time predicts the efficacy of site-directed therapy for oligoprogressive castration-resistant prostate cancer

H. Kume, S. Taguchi, T. Nakagawa, 2023, Prostate International.